BTCC / BTCC Square / Global Cryptocurrency /
UniQure Stock Surges 248% on Breakthrough Huntington’s Trial Results

UniQure Stock Surges 248% on Breakthrough Huntington’s Trial Results

Published:
2025-09-25 08:57:02
8
2
BTCCSquare news:

UniQure (QURE) shares skyrocketed 248% following promising clinical trial results for its AMT-130 gene therapy, showing a 75% slowdown in Huntington's disease progression. The breakthrough triggered a parallel 59% rally in partner ClearPoint Neuro (CLPT) stock.

The biotech firm secured a $175 million non-dilutive loan facility from Hercules Capital (HTGC) to support potential commercialization. Wall Street analysts responded with multiple price target upgrades, signaling renewed confidence in the company's pipeline.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users